Information Provided By: 
Fly News Breaks for May 23, 2018
VNDA
May 23, 2018 | 07:34 EDT
Citi analyst Joel Beatty initiated Vanda Pharmaceuticals with a Buy rating and $26 price target. The company's 2018 sales are on track to be $180M-$200M, which largely supports the current enterprise value of $610M, Beatty tells investors in a research note. He believes upside in 2018 could come from sales growth plus a label expansion for Hetlioz, and Phase 2 tradipitant data. Further, late-stage pipeline agent tradipitant offers " nearly a free call option," the analyst contends.
News For VNDA From the Last 2 Days
